OncoSec Granted New Patent from China

OncoSec‘s New Patent For OMS Electroporation Device Approved By China

Online PR News – 06-September-2012 – SAN DIEGO – SAN DIEGO – September 5, 2012 – OncoSec Medical Inc. (OTCBB: ONCS), a company

developing its advanced-stage ImmunoPulse and NeoPulse technologies to treat

solid tumor cancers, received a new Method of Use and Device patent (Patent

Application No. 200780014313.0, “Method and Device for Treating Microscopic

Residual Tumors Remaining in Tissues Following Surgical Resection”) for the

OncoSec Medical System (OMS) electroporation device platform from the State

Intellectual Property Office of the People’s Republic of China. The issuance

of this patent has the potential to expand OncoSec’s commercial opportunities

for minimally invasive and surgical procedures to treat solid tumors in a very

large market such as China.

Punit Dhillon, OncoSec’s President and CEO, commented, “The issuance of this

patent is significant, because the Chinese authorities have given the company

patent approval for our claims regarding the OMS electroporation device

itself, as well as the method of use. These are broad claims, wherein OncoSec

now has the ability to deliver various therapeutic agents through its

electroporation device, including bleomycin and DNA IL-12, as well as to treat

tumors with these agents following surgical resection. Thus, this patent will

act as a part of the company’s core strategy as we continue to develop and

build our commercialization strategy in China, one of the largest emerging

oncology markets.”

Numerous research studies have concluded that cancer has now become a leading

cause of mortality in China, representing 25 percent of all deaths in urban

areas and 21 percent in rural areas. Moreover, cancer mortality in China has

been increasing rapidly and continuously during the past three decades, which

indicates a significant need for novel therapies.

ImmunoPulse and NeoPulse are investigational therapies being evaluated to

reduce the rate of cancer recurrence while minimizing quality-of-life side

effects. These therapeutic approaches, as potential adjuncts to surgery,

involve injecting the tumor with an anti-cancer agent, followed by

electroporation to open up the cell membrane, which helps significantly

increase the uptake of the agent. This approach has been shown to selectively

kill cancer cells that may exist in the neighboring tissue, which may result

in a reduced rate of recurrence and has the potential to complement standard-

of-care surgical procedures.